Non Alcoholic Steatohepatitis Clinical Trial
Official title:
Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization
Live donor liver transplantation (LDLT) is the treatment of choice for end-stage liver disease, predominantly in the East, where deceased donor liver transplantation is sparse. In LDLT, donor selection has to be stringent; as the donor safety is thepriority. Live liver donors (LLD) with complex biliary and vascular anatomy are increasingly being accepted for donation with the betterment of technical expertise. One of the commonest reasons for LLD rejection is the hepatic parenchymal abnormality because ofsteatosis and steatohepatitis, which can increase the donor risk. Retrospective analysis of donors with non-alcoholic steatohepatitis(NASH) who were optimized and taken up for major hepatectomy from June 2011 to January 2018will be performed.
Study Design Aim and Objective -
- Primary objective:
- To study the effect of donor optimization protocol in donors with biopsy proven NASH
- To study thebiochemical (LFTSs & INR) recovery in donors with NASH after major
hepatectomy
- To compare their biochemical recovery parameters (LFTs & INR) with that of non NASH
donors.
- Secondary objectives:
- To study incidence of NASH among live liver donors
- To study their respective recipients' outcomes
- To study the morbidity among LLDs with NASH after major hepatectomy
Methodology:
- Study population:Patients underwentLDLT from June 2011 to January 2019 at Institute of
Liver & Biliary Sciences, New Delhi
- Study design:Retrospective study
- Study period:from June 2011 to January 2019
- Sample size with justification:All consecutive LLDs with at least one year of follow up
post-operatively
- Intervention: none
- Monitoring and assessment:none Statistical Analysis:Categorical variables were presented
as number (percentage) and were compared using the Chi-square test. Continuous variables
were presented as mean (standard deviation, SD) and were compared using Mann-Whitney U
Test.
Adverse Effects: None Stopping Rule of Study: None
Expected Outcome of the Project: Adherence to a strict dietary and lifestyle modifications
plan will cause histological reversal of NASH and fibrosis in LLDs. Their clinical and
biochemical recovery following the major hepatectomy will be similar to that of non-NASH
LLDs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Completed |
NCT01695083 -
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
|
||
| Not yet recruiting |
NCT05605158 -
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
|
Phase 3 | |
| Completed |
NCT01761370 -
Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)
|
N/A | |
| Completed |
NCT03432377 -
Coffee Consumption and NASH in the French Population.
|
||
| Withdrawn |
NCT03864835 -
NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal
|
N/A | |
| Completed |
NCT05357352 -
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
|
||
| Not yet recruiting |
NCT03803540 -
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
|
Phase 1 | |
| Completed |
NCT02395900 -
The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT01791959 -
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05821010 -
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT03734510 -
The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study
|
N/A | |
| Recruiting |
NCT02721264 -
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
|
N/A | |
| Terminated |
NCT03883607 -
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT03863574 -
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT03377153 -
The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT03377140 -
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
|
N/A | |
| Active, not recruiting |
NCT04669158 -
Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06176079 -
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
|